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Centronuclear myopathies (CNMs) are genetic diseases whose symptoms are muscle weakness and atro-
phy (wasting) and centralised nuclei. Recent human genetic studies have isolated several groups of muta-
tions. Among them, many are found in two interacting proteins essential to clathrin-mediated
endocytosis, dynamin and the BIN-Amphiphysin-Rvs (BAR) protein BIN1/amphiphysin 2. In this review,
by using structural and functional data from the study of endocytosis mainly, we discuss how the CNM
mutations could affect the structure and the function of these ubiquitous proteins and cause the muscle-
specific phenotype. The literature shows that both proteins are involved in the plasma membrane tubu-
lation required for T-tubule biogenesis. However, this system also requires the regulation of the
dynamin-mediated membrane fission, and the formation of a stable protein-scaffold to maintain the T-
tubule structure. We discuss how the specific functions, isoforms and partners (myotubularin in partic-
ular) of these two proteins can lead to the establishment of muscle-specific features.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Muscles are essential to animal life. Among the different types
of muscles, skeletal muscles are involved in coordinated move-
ment, such as walk. Brain neuronal influx orchestrates the contrac-
tion and relaxation cycles of the many muscles involved in a
specific move. The importance of the correct transduction of such
signals within muscle cells is revealed in human diseases where
it is impaired. One of these is a group of hereditary diseases with
several genetic determinants called centronuclear myopathies
(CNMs). The onset, severity and progressiveness vary a lot between
different CNM subtypes, but the common symptoms are muscle
weakness and the histological phenotype that cell nuclei are
abnormally located in the centre of the muscle fibres instead of
at the periphery, just below the plasma membrane, giving its name
to the disease. This histological phenotype may be a signature of
muscle fibres not being fully differentiated. Central nuclei are pre-
sent in many forms of myopathies, as a consequence of excessive
muscle fibre regeneration, due to fibre loss. However, in CNM, noexcessive regeneration occurs, and the central position of nuclei
is thought to arise from a block in muscle fibre development. How-
ever, it could also be that the mutation interferes with the process
that locates the nuclei at the periphery, without affecting the mus-
cle functionality.
Almost a decade ago, the first cases of CNM patients with a
mutation in the BAR domain (Bin-Amphiphysin-Rvs) protein
BIN1 and in dynamin 2 were reported (Bitoun et al., 2005; Nicot
et al., 2007). These proteins are ubiquitously expressed and impor-
tant players of clathrin-mediated endocytosis, where they have a
membrane remodelling activity. The aim of this review is to
describe how the properties and functions of these proteins discov-
ered in endocytosis can help in understanding the muscle-specific
function of these proteins, and how mutations causing CNM would
trigger the symptoms.2. BIN1 in CNM
2.1. BIN1, a crescent-shaped protein able to tubulate membranes
BIN1, a close homologue of the endocytic protein amphiphysin
1 (54% identity) and therefore also called amphiphysin 2, was
initially identified as the box-dependent myc-interacting protein
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its discovery, it was observed to be located in the proximity of T-
tubules in skeletal muscles (Butler et al., 1997). T-tubules are long
tubular invaginations from the myocyte plasma membrane into
the actin fibre organization. They are parallel to the Z-lines of sar-
comeres and allow the propagation of the myocyte plasma mem-
brane depolarisation, triggered by the neuronal action potential.
Once in the T-tubules, the depolarization induces the release of cal-
cium from sarcoplasmic membranes adjacent to T-tubules. The cal-
cium further induces myosin activity, and muscle contraction.
BIN1 was first proposed to play a role in muscle cell differenti-
ation based on the results that myoblasts had difficulties to differ-
entiate into myotubes when BIN1 was downregulated (Wechsler-
Reya et al., 1998). But it was intriguing to find such similarities
between amphiphysin 1 in clathrin-mediated endocytosis (CME)
and BIN1 in the T-tubule system. In Drosophila, the single amphi-
physin gene accounts for both the endocytic function of human
amphiphysin 1 and the muscular function of BIN1, as it is located
at both endocytic pits and in the proximity of tubular structures
resembling T-tubules in flies (Razzaq et al., 2001). Strikingly, the
homozygous null mutant was viable and did not have a significant
phenotype in endocytosis of synaptic vesicles, but had a severe
phenotype in the muscle contraction and was therefore flightless.
Confocal sections revealed that the T-tubule system was present
but highly disorganised in the fly muscle, suggesting that the Dro-
sophila amphiphysin/BIN1 homolog participates to the T-tubule
biogenesis.
BIN1 belongs to the BAR protein family (BIN1/Amphiphysin/
Rvs167; Sakamuro et al., 1996), a protein family which shares
the BAR domain. The BAR domain is the lipid membrane binding
domain, and forms dimers of the shape of a crescent (Peter et al.,
2004). The BAR domain dimer binds to negatively charged lipids
via its positively charged concave face (Casal et al., 2006; Peter
et al., 2004). Because of its crescent shape, it was shown to bind
membranes in a curvature-dependent manner, and is thus consid-
ered as a membrane-curvature sensing module (Antonny, 2011).
BIN1 further belongs to the subclass of N-BAR proteins as it also
contains an N-terminal amphipathic helix. Amphipathic helices
are sequences of 15–30 amino acids in which, once folded into
an a-helix, the hydrophobic residues are positioned on one face
and the hydrophilic residues on the opposite face of the helix
(see also Fig. 2A; Segrest et al., 1974). They are unfolded in solution
and fold into an a-helix while binding to the lipids (velcro model,
Antonny, 2011). Point mutations of hydrophobic residues within
the amphipathic helices strongly affect liposome binding and tubu-
lation of the two N-BAR proteins endophilin and amphiphysin 1Fig. 1. BIN1 and dynamin 2 domain structure. BIN1, upper panel. Dynamin 2, lower p
numbers are indicated on the left, the tissues in which the isoforms are expressed on the
isoforms in this tissue.(Farsad et al., 2001). Thus, these amphipathic helices are often con-
sidered as curvature-inducer modules. But amphipathic helices are
also proposed to sense curvature and other intra-membrane stres-
ses (Campelo and Kozlov, 2014) as well as to be involved in mem-
brane fission (Boucrot et al., 2012). The structure of BIN1’s N-
terminal amphipathic helix in micelles was solved by NMR by
Löw et al. (2008) and shows that roughly 20 residues belong to
BIN1’s N-terminal amphipathic helix. Thus, the BAR domain of
BIN1 has structural features, like other N-BAR domains, with cur-
vature sensing, and curvature-inducing capabilities. As it was
shown that the balance between those two activities strongly
depends on the BAR domain density on the membrane (Sorre
et al., 2012), one can wonder whether the BAR domain of BIN1 is
a curvature sensor or a curvature inducer in the physiological con-
text of the T-tubule biogenesis.
Another domain present in all BIN1 isoforms is an Src homology
3 (SH3) domain which interacts with several Proline-Rich Domains
(PRDs), including the one of dynamin (Grabs et al., 1997), another
protein mutated in several CNM-patients (see next part). This
domain is thus expected to play a major role in the combined
action of BIN1 and dynamin in T-tubule biogenesis (see second
part).
BIN1 has two muscle-specific isoforms (including vs. excluding
exon 17), which contain peptide sequences with muscle-specific
properties. BIN1 has 20 exons, which are differentially spliced into
11 isoforms (Uniprot ID O00499, UGID 160989; Fig. 1). BIN1 amino
acid numbers refer to the position in the canonical isoform 1 in this
review. In these muscle-specific isoforms, the clathrin-AP2 (CLAP)
binding motif, which targets BIN1 to clathrin-coated pits, is not
present, arguing for a role independent of CME in the muscle
(Ramjaun and McPherson, 1998). Moreover, only the muscle speci-
fic isoforms of BIN1, sometimes referred to as M-Amph2, contain
translated exon 11. Exon 11 was found to specifically bind to PI
(4,5)P2 and PI(4)P (Lee et al., 2002) and therefore named phospho-
inositide (PI) domain. It should be noted that exon 11 was previ-
ously named exon 10 (e.g. Lee et al., 2002; Wechsler-Reya et al.,
1997) because an additional exon in the BAR domain had been
overlooked (current name exon 7 (NCBI), exon a–b from Tsutsui
et al., 1997). The overexpression of BIN1 isoform 8, which contains
the PI motif, was found to induce membrane tubulation in several
cell types (Nicot et al., 2007; Lee et al., 2002), while this was not
observed for the neuronal isoform 1 which does not contain the
PI motif. This led to the proposition that the PI motif is required
for the tubulation activity of BIN1, suggesting a role in the
formation of T-tubules. Lee et al. (2002) proposed that PI(4,5)P2,
whose concentration increases during myoblast-to-myotubeanel. Arrowheads indicate positions of CNM-linked mutations. For BIN1, isoform
right. Semi-transparency of exons indicates alternative splicing within the different
Fig. 2. Structural consequences of CNM-linked mutations in BIN1. A. Helical wheel projection of residues 18-36 (amphipathic helix) from human BIN1 and likely new
positioning due to DK21, R24C and K35N. B. Affected residues of truncation of SH3 domain. Lacking parts in human K575X mutant in violet; human F588 (blue) is part of
dynamin binding face (green); crystal structure from rat BIN1 (Owen et al., 1998). Charged residues are marked in violet (positive) and blue (negative), hydrophobic residues
in green and polar uncharged residues in grey. C, D. D151 and R154 are on the tip of the BIN1 BAR domain dimer and point sideways. Visualisation of a BAR domain dimer
from the front, with each monomer in a different grey shade (C). Side view (D).
Table 1
CNM mutations in BIN1.
Mutation Exon Domain Dominance Severity Disease onset BIN1 phenotype Reference of discovery
DK21 1 H0 Dominant Mild Adulthood Tubulation defect (in vivo) Böhm et al. (2014)
R24C 1 H0 Dominant Mild Adulthood Tubulation defect (in vivo) Böhm et al. (2014)
K35N 2 H0 Recessive Variable Neonatal Tubulation defect (only in vivo) Nicot et al. (2007)
D151N 6 BAR Recessive Mild Childhood Tubulation defect (in vivo/in vitro) Nicot et al. (2007)
R154Q 6 BAR Recessive Intermediate Childhood Tubulation defect (in vivo/in vitro) Claeys et al. (2010)
IVS10-1G > A 11 PI Recessive Variable Childhood Tubulation defect (in vivo/in vitro) Böhm et al. (2013)
Q573X 20 SH3 Recessive Intermediate Neonatal [Not tested] Böhm et al. (2010)
K575X 20 SH3 Recessive Intermediate Neonatal or childhood Dynamin binding defect Nicot et al. (2007)
P593HfsX54 20 SH3 Dominant Mild Adulthood [Not tested] Böhm et al. (2014)
X594DfsX53 20 SH3 Dominant Mild Adulthood [Not tested] Böhm et al. (2014)
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P2-rich plasma membrane compartments, leading to membrane
tubulation and T-tubule formation. The affinities for the different
phosphoinositides PI(3)P, PI(4)P, PI(5)P and PI(4,5)P2 is still a mat-
ter of debate (Fugier et al., 2011; Picas et al., 2014), but the PI motif
of BIN1 is needed for correct muscle function and localisation of
BIN1 in the muscle (Böhm et al., 2013). The role of the PI motif
would thus be to locally increase BIN1 protein density onto the
membrane in a PIP-dependent manner, promoting curvature
induction towards curvature-sensing functions, as shown by
Sorre et al. (2012) for amphiphysin 1. In this case, BIN1 would
actively participate in the tubulation of the plasma membrane into
a T-tubule system. This scenario is consistent with the fact that the
T-tubule system is disrupted in patients with mutations within the
PI motif (see below).The PI motif was not only found to bind to phosphoinositides
but also to the BIN1 SH3 domain (Kojima et al., 2004). Exchanging
the PI motif in BIN1 by a different phosphoinositide binding
domain without affinity for SH3 domains (PH domain of PLCd)
resulted in abnormal morphology of nascent T-tubules (Kojima
et al., 2004). This result could be explained by competitive interac-
tions between PIPs, PI, SH3 and dynamin PRD domains. Wu and
Baumgart (2014) determined binding affinities for these different
interactions and came to the conclusion that the affinity of the
SH3 domain is higher for its own PI motif than for dynamin’s
PRD domain (Kd 10 lM and 66 lM, respectively). They also found
that the Kd of the PI motif for PI(4,5)P2 was too high to be measured
by isothermal titration calorimetry (ITC), but high PRD domain
concentrations increased BIN1 membrane binding, suggesting that
the SH3 domain is released from the PI motif when the SH3 domain
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ues for full-length BIN1 binding to PIPs are very low (all below
2 lM; Fugier et al., 2011), making it the strongest interaction of
all three. Thus a possible scenario could be that the phosphoinosi-
tide binding of the full-length BIN1 would cause the release of the
SH3/PI domain interaction, allowing the SH3 domain to bind to
dynamin’s PRD domain, and recruiting dynamin to T-tubules (Lee
et al., 2002).
All these domains have mutations causing various forms of
CNM. In the following, we review these mutations, and try to
pinpoint the specific function disabled in each of these, and discuss
the role of BIN1 in the specific context of the muscle.
2.2. BIN1 mutations found in CNM patients
Based on the observation that the Drosophila Amphiphysin/BIN1
null mutant led to a disorganised T-tubule system, Razzaq et al.
(2001) proposed that BIN1 mutations might be responsible for
myopathies. In 2007, such mutations were indeed reported
(Nicot et al., 2007). The authors analysed a group of CNM patients
with consanguineous parents, therefore potentially having
homozygous mutations. The MTM1 gene, coding for myotubularin,
a lipid phosphatase involved in the production of a precursor of PI
(4,5)P2 and already shown to cause CNM when mutated, was not
mutated in those patients. The authors sequenced BIN1 due to
the known link of BIN1 with muscles and PIPs and identified three
mutations that were segregating, when homozygous, with the
CNM symptoms. Since then, seven further BIN1 mutations were
identified (Böhm et al., 2010, 2013, 2014; Claeys et al., 2010), out
of which four caused a mild version of CNM already when
heterozygous, leading to ten currently known CNM-linked BIN1
mutations (see Table 1).
The mutations locate to the BAR domain, its N-terminal amphi-
pathic helix, the PI motif and the C-terminal SH3 domain (see
Fig. 1). Mutations in the PI motif are expected to have a muscle-
specific phenotype, since only muscle isoforms of BIN1 contain this
domain. But it is interesting to note that most of the found CNM-
linked mutations affect the N-BAR and SH3 domains that are pre-
sent in all isoforms of BIN1, leading to the question of how such
mutations could lead to a muscle-specific disease.
2.3. CNM-linked mutations in the N-terminal amphipathic helix of
BIN1 could decrease the stability of the BIN1 scaffold
In the following, we are going through the different BIN1 muta-
tions in more detail. Three mutations (DK21, R24C, K35N; Böhm
et al., 2014; Nicot et al., 2007) locate to the amphipathic helix at
the N-terminus of the BAR domain of BIN1. In the R24C and
K35N mutations, positively charged residues are replaced by
hydrophobic or polar uncharged residues. In the DK21 mutation,
three nucleotides are deleted, leading to a deletion of positively
charged lysine 21 without frame shift and a shift in the amino acid
sequence on the helical wheel (see Fig. 2A). When K21 is absent,
the original lysine at this helical wheel position should be unaf-
fected because lysine 20 will likely take over this position. In con-
trast, the polar uncharged amino acid Q19 should take over the
position of the charged K20, meaning that this should be the actu-
ally affected helical wheel position of the DK21 deletion.
The three residues affected by the above mutations are all in the
polar face of the helical wheel and very close to each other. These
mutations are thus expected to strongly interfere with the struc-
ture of the amphipathic helix (see Fig. 2A), and thus with its ability
to bind and cause membrane curvature. In the three mutations
found in the amphipathic helix of BIN1, positively charged amino
acid positions in the wheel projection are replaced by uncharged
amino acids, while the hydrophobic face of the helical wheelremains almost unaffected. This underlines the importance of the
positively charged residues 20, 24 and 35, which interact with neg-
atively charged lipids of the plasma membrane to trigger proper
helix folding into the membrane (Antonny, 2011).
For these three mutations, BIN1’s tubulating activity upon over-
expression was decreased in cells (Böhm et al., 2014; Nicot et al.,
2007; Wu et al., 2014). No in vitro tubulation data were available
for the DK21 and R24C mutants but one study tested the K35N
mutant’s tubulating activity in vitro and did not observe significant
differences to the WT (Wu et al., 2014). However, they observed
decreased membrane binding of the K35N BIN1 N-BAR compared
to WT. One might speculate that the K35N mutant has a defect
in membrane tubulation because of reduced membrane binding,
but in vitro, where high protein concentrations are used, the
membrane is probably saturated with protein regardless of its
binding efficiency. Consistently, DK21 and R24C cause CNM
already in the heterozygous state, while K35N only when homozy-
gous. The reduced tubulation activity of K35N-BIN1 could be com-
pensated by co-overexpressing wild-type BIN1, while this was not
the case for the DK21 and R24C mutants (Böhm et al., 2014), con-
firming the dominant effect of the latter two mutations.
But the deleterious effect of these mutants may come from
another reason. Mim et al. (2012) found that the N-terminal
amphipathic helix of endophilin, another N-BAR protein, forms
homo-interactions between helix rungs, and that these interac-
tions are crucial for the formation of the N-BAR lattice on a mem-
brane tube. A similar observation was recently made for the BIN1
lattice (Adam et al., 2015). Thus, the deleterious effect on T-
tubule biogenesis of CNM-linked BIN1 mutations in the amphi-
pathic helix might be linked to its role in the assembly of the
BIN1 scaffold.
The possible configurations of interacting amphipathic helices
in the helical scaffold had two energetically favourable positions
(Mim et al., 2012). In one case, the two helices interacted over
the whole length while in the other they were slightly shifted by
about a third of their length. In this shifted position, the C-
terminal residues of the amphipathic helix should then be less cru-
cial for the polymerization of BIN1 as they would not participate in
the rung interactions. This could explain why DK21 and R24C
cause CNM already in the heterozygous state while adults carrying
a heterozygous K35N mutation had no symptoms, as K35 is one of
the last residues of the amphipathic helix (Löw et al., 2008). It
should be noted that the few adults with known heterozygous
K35N mutation (Nicot et al., 2007) were parents of young children
and therefore one cannot exclude that they also develop(ed) symp-
toms of heterozygous CNM later in their life, after publication of
the study.
2.4. CNM-linked mutations in the BAR domain of BIN1 decrease its
tubulation property
Two recessive mutations causing CNM were found in the BAR
domain itself (Claeys et al., 2010; Nicot et al., 2007). In both muta-
tions (D151N, R154Q), single charged amino acids are replaced by
polar uncharged ones. From their position in the concave face of
the BAR dimer (Fig. 2C and D), it is expected that the mutated resi-
dues participate in membrane binding. Indeed, the position of the
two mutations is at tips of the BIN1 dimer, and a cryo EM structure
of BIN1 bound to membrane tubes shows that the tip regions of the
BIN1 BAR are deeply inserted into the membrane (Adam et al.,
2015). This would fit with the sideways/upwards facing residues
affected in these mutants. Also, heterodimers of WT and D151N
(or R154Q) could form, explaining the recessive character of these
mutations.
Surprisingly, both mutations affect exon 6, which is present in
all BIN1 isoforms. All BIN1 isoforms should therefore be affected,
A. Hohendahl et al. / Journal of Structural Biology 196 (2016) 37–47 41and not only the muscle-specific isoform 8. Thus, the observed
tissue-specificity of the mutant phenotypes of D151N and R154Q
must arise from a tissue-specific function or a tissue-specific set
of partners. In contrast to the K35N (N-terminal amphipathic helix)
mutant, the decrease in membrane tubulation in cells was also
observed in vitro (Picas et al., 2014; Wu et al., 2014). Membrane
binding of the D151N and R154Q mutants was decreased (Wu
et al., 2014) and their localisation was different from WT BIN1 in
the muscle (Böhm et al., 2013; Toussaint et al., 2011). The onset
of CNM in patients with D151N or R154Q BIN1 is later than in
those having the K35N mutation (childhood vs. embryonic onset).
Furthermore, K35N-CNM is more severe (Claeys et al., 2010; Nicot
et al., 2007), suggesting that the amphipathic helix function might
be more important for BIN1’s muscular function than the one
changed in the D151N and R154Q BIN1 mutants. The fact that
K35N-CNM is more severe may account for another function of
the amphipathic helix than simply the proposed tubulation prop-
erty (observed in cells), as the D151N and R154Q BIN1 mutants,
for which the tubulation decrease was even confirmed in vitro,
have a stronger tubulation phenotype but milder CNM symptoms
and onset. As proposed above, this ‘‘second” function of the amphi-
pathic helix could be the formation of interactions between adja-
cent turns of the helix, helping polymerization of BIN1.
It has been proposed that the crescent shape of BAR domains
and the amphipathic helices have two distinct roles: while the
crescent shape of BAR domains would sense membrane curvature,
the amphipathic helices would actually induce it (Boucrot et al.,
2012; Farsad et al., 2001). The CNM-related BIN1 mutants in these
regions were not going along this proposition. While a mutation in
the amphipathic helix should have resulted in a membrane tubula-
tion defect, no significant tubulation defect was observed in vitro
(K35N, Wu et al., 2014). The D151N and R154Q mutants should
have shown a membrane curvature sensing defect instead of show-
ing reduced membrane tubulation, whereas the opposite was
observed (Wu et al., 2014).
2.5. CNM-linked BIN1 mutations in the muscle-specific PI motif
decrease BIN1’s membrane tubulation properties
Only one known CNM-linked mutation affects the PI motif, the
domain which specifically interacts with phosphoinositides (Lee
et al., 2002). The progression of this type of CNM was very rapid
upon the onset of the disease, two out of three patients died 2–
4 years after the onset. This mutation is a splice acceptor site muta-
tion (Böhm et al., 2013). The splice donor site at the end of exon 10
mistakenly binds to the splice acceptor site of exon 12, as the splice
acceptor site of exon 11 is mutated (IVS10-1G > A; intervening
sequence 10, position 1, G-to-A conversion). Only the muscle-
specific isoforms 8 and 10 (Fig. 1) are affected by the mutation
because the splice acceptor site of exon 11 is anyway not used in
the other isoforms. The tissue-specificity of the IVS-1G > A muta-
tion is thus far more easy to explain than for the other BIN1 muta-
tions causing CNM. With this mutation, isoforms 8 and 10 are
reverted to the ubiquitous form, therefore patients do not express
muscle-specific isoforms. Thus, it is predicted that in these
patients, the muscle-specific properties of BIN1, in particular the
specific, phosphoinositide dependent, recruitment to the plasma
membrane to induce T-tubule formation, should be lost. Indeed,
the localisation of BIN1 in the muscle was observed to be altered
in patients with this mutation (Böhm et al., 2013). Also, the tubu-
lation was decreased in cultured myotubes and in vitro experi-
ments (Böhm et al., 2013; Wu and Baumgart, 2014) when
comparing BIN1 with and without the PI motif. The CNM-
phenotype of the IVS10-1G > A mutation drastically illustrates
either or both of the following hypotheses. The first hypothesis
would be that the specific recruitment of BIN1 tophosphoinositides is indeed crucial for the proper muscle-specific
function of BIN1. The second hypothesis is based on the observa-
tion (see next sub-chapter for more detail) that the PI motif can
also bind to the SH3 domain (Kojima et al., 2004; Wu and
Baumgart, 2014). This interaction could be inhibitory, and partici-
pate in the regulation of dynamin recruitment by BIN1 bound to
phosphoinositides (see discussion below). This would explain also
that mutants lacking the PI motif have similar effects in patients
than hyperactive dynamin 2 mutants (see discussion below).
The variability of the CNM onset may account for different func-
tions of BIN1 during development and maintenance of muscles.
Strikingly, the skeletal muscle phenotype of bin1 morphant zebra-
fish embryos, notably the disorganization of triads, could be res-
cued by both BIN1 with the PI motif (isoform 8) and BIN1
without the PI motif (isoform 9) (Smith et al., 2014). This supports
a specific role of the PI motif during muscle maturation and main-
tenance rather than during early development (Smith et al., 2014).
2.6. CNM-linked BIN1 mutations in the SH3 domain decrease the
interaction with dynamin
The SH3 domain of BIN1 is important for its interaction with
PRD-domain-containing proteins like dynamin and is present in
all 11 isoforms reported till today (Uniprot), therefore mutations
in the SH3 domain also affect the neuronal and ubiquitous iso-
forms. In this case, explaining the tissue-specificity of the induced
muscle phenotype revealed complex. Four CNM mutations were
found in this domain so far (Böhm et al., 2010; Böhm et al.,
2014; Nicot et al., 2007). Two of these, Q573X and K575X, lead to
a 20%-truncation of the SH3 domain amino acid sequence due to
premature stop codons (Böhm et al., 2014; Nicot et al., 2007) while
the other two, P593HfsX54 and X594DfsX53, cause a frame shift
and add 52 additional amino acids to the SH3 domain (Böhm
et al., 2014). No functional studies for these last two mutations
have been reported yet, making it difficult to draw conclusions
on the disease mechanism. Both are dominant mutations and cause
mild and late-onset CNM already in the heterozygous case, in con-
trast to the SH3-domain-truncating mutations Q573X and K575X
whose heterozygous carriers are healthy but which cause a more
severe CNM with early onset when homozygous.
There are several functional studies about the K575X mutant,
which could also account for the effect of the Q573X mutation
due to their very similar SH3-domain truncations. In both mutants,
the last a-helix and the last two b-sheets of the SH3 domain are
missing (Fig. 2B and Owen et al., 1998). The first consequence is
likely a destabilisation and potential misfolding of the whole SH3
domain, because the two deleted b-sheets are normally part of a
b-barrel which forms the inner scaffold of many SH3 domains
(Owen et al., 1998). The second consequence is that the dynamin
binding site is lacking an important hydrophobic residue (F588)
in the K575X mutant, required for dynamin binding in vitro
(Owen et al., 1998). The decreased dynamin-binding capacity of
the truncated K575X mutant was indeed confirmed in vitro
(Nicot et al., 2007). The K575X mutation did not affect the mem-
brane tubulation ability of overexpressed BIN1 in COS-1 cells
(Nicot et al., 2007). In contrast, and as expected, dynamin was
not recruited to these tubules (Nicot et al., 2007). A recent study
tested whether the recruitment of dynamin to BIN1 positive struc-
tures was only mediated via direct dynamin 2-BIN1 interactions
(Picas et al., 2014) or via dynamin’s known curvature sensing prop-
erties (Roux et al., 2010). The results suggested that dynamin 2
recruitment to BIN1 positive membrane tubules might also be
due to BIN1’s ability to cluster PIPs, which in turn recruit dynamin
2. Additionally, the SH3 domain of BIN1 could of course still recruit
dynamin to these regions via a direct interaction with dynamin’s
PRD domain. This would speak for the fact that BIN1 can still
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case of the K575X mutant (Nicot et al., 2007).
A difficulty in unfolding the disease mechanism of the K575X
BIN1 mutant lies in the ability of the PI motif to interact with the
WT SH3 domain but not with the K575X SH3 mutant (Wu and
Baumgart, 2014). Since this mutant shows an increase in mem-
brane tubulation in vitro (Wu and Baumgart, 2014), it has been
proposed that the SH3-PI interaction may play as an intra-
molecular inhibition, which could be released by BIN1 binding to
either the membrane or dynamin. The increased curvature induc-
ing properties of the K575X-mutated protein would therefore
result from a decreased autoinhibition.
But the primary role of BIN1’s SH3 domain is to bind to dyna-
min. Dynamin is a GTPase that tubulates lipid membranes by form-
ing helical polymers around membrane tubes. It also constricts the
membrane, leading to fission upon GTP hydrolysis. In the follow-
ing, we describe the effect of the mutations found in dynamin 2
in some CNM-related mutations, and discuss the interplay
between dynamin and BIN1 in the specific case of the T-tubule
biogenesis.3. Dynamin 2 in CNM
Dynamin is a large GTPase that mediates membrane fission at
the final step of clathrin-mediated endocytosis. Dynamin polymer-
izes around the neck of clathrin-coated buds and severs the mem-
brane upon GTP hydrolysis, in order to release the vesicle in the
cytoplasm. Other less known functions comprise roles in clathrin
independent endocytosis and actin dynamics (Ferguson and De
Camilli, 2012).
In mammalian cells there are three dynamin genes that share a
similar sequence and the same domain structure. Dynamin 1 is
expressed in the brain, dynamin 2 is ubiquitous and dynamin 3
is expressed in lungs, testis and brain (Cao et al., 1998). Dynamins
are constituted of five domains, starting from the N-terminus with
the G-domain, in charge of GTP hydrolysis. It is connected to the
rest of the protein through a flexible hinge called the Bundle Sig-
naling Element (BSE or neck). At the other side of the BSE, the
‘‘stalk” region comprises two distinct sequence parts, the middle
domain and the GTPase Enhancing Domain (GED). The stalk region
mediates dimer formation and further interactions that allow self-
assembly. The Pleckstrin Homology (PH) domain binds the plasma
membrane through specific phosphoinositides (especially PI(4,5)
P2). As discussed above, the PRD domain is deputed to the binding
to and recruitment of other proteins, in particular BIN1. It defines
the specific functions of the three dynamins as its sequence is
the most variable between variants, allowing for differential bind-
ing of dynamin partners (Faelber et al., 2011; Raimondi et al.,
2011). Dynamin function in membrane fission involves its GTPase
activity that is up regulated by polymerization and lipid binding
(Smirnova et al., 1999; Warnock et al., 1996), allowing the action
of dynamin to be maximal only when polymerized at the mem-
brane neck. Structural data showed that in absence of nucleotide,
the PH domain is flipped-back onto the stalk, having specific inter-
actions (Faelber et al., 2011) with both the stalk and the GTPase
domain, that were broken upon polymerization (Reubold et al.,
2015). Thus, it was proposed that the PH domain, when flipped
and bound to the stalk and the GTPase domain, would be an inhi-
bitory ‘‘closed” state of dynamin which would be release when the
PH domain would bind the membrane, activating the GTPase and
the polymerization of dynamin.
Specific heterozygous mutations in the ubiquitous dynamin 2
(Uniprot ID P50570-1, UGID 164319) lead to autosomal dominant
centronuclear myopathy (ADCNM) (Bitoun et al., 2005). The clini-
cal aspects of ADCNM caused by mutations of dynamin 2 arevariable depending on the specific mutation involved (Bitoun
et al., 2009b), and occasionally even for the same mutation.
ADCNM can have mild, intermediate or severe forms. The age of
onset is also very variable and ranges from early (neonatal and
childhood) and intermediate (adolescence) to late onset (adult-
hood) (Böhm et al., 2012).
The only tissue that is affected by CNM-related dynamin 2
mutations is the muscle, but the mutations causing CNM involve
the ubiquitous dynamin 2 whose functions are necessary in the
whole organism. How a tissue-specific disease can be caused by
mutations in a ubiquitous protein is still unclear, but analysing
the effect of these mutations at the biochemical and functional
levels supports a muscle-specific structural role of dynamin 2 inde-
pendent of its function in membrane fission.3.1. Biochemical, structural and cellular aspects of CNM-related
dynamin 2 mutations
ADCNM shares the major cellular and sub-cellular phenotypes
with other forms of CNM such as centralized nuclei, predomi-
nance of type I fibres (slowly contracting and less power-
generating than type II fibres), muscle weakness and atrophy.
But it also implicates an abnormal radial distribution of sar-
coplasmic strands not found in CNM caused by the mutations
of other genes (Böhm et al., 2012).
Among the mutations of dynamin 2 that cause CNM, the major-
ity are missense mutations located in the stalk (middle and GED
domains) and in the PH domain. All the mutations that have been
biochemically characterized (R465W, S619L, A618T, E368K, DV625
and R369W) show an increase in basal GTPase activity and less
GTP-induced disassembly as compared to wild type dynamin 2
(Chin et al., 2015; James et al., 2014; Kenniston and Lemmon,
2010; Wang et al., 2010). R369W, S619L andDV625 have also been
shown to have a higher ability to self-assemble, which may
account for their reduced disassembly rate. Their basal GTPase
activity is higher than the wild type, but does not increase upon
assembly. Thus, biochemical data available for these mutations
show a gain of function phenotype, both for assembly and for
GTPase activity, suggesting that the auto-inhibitory mechanism
discussed above for the PH domain is not functional in these
mutants. Indeed, among the CNM-related dynamin 2 mutations,
the majority is positioned at the interface (or in close proximity)
between the stalk and the PH domain in the dimer structure in
absence of nucleotide (see Table 2 and Fig. 3). Moreover, the major-
ity of CNM-related mutations in this interface locally change the
charge or the hydrophobicity of the residues and could be
accounted for a major disruption of the interface. Although no data
is available for other CNM-related mutations in this interface
(E368Q, R369Q, F372C, V375G, D614N, A618D, L621P, P627R and
P627H) (Bitoun et al., 2005; Böhm et al., 2012; Catteruccia et al.,
2013; Echaniz-Laguna et al., 2007; Jungbluth et al., 2010;
Kierdaszuk et al., 2013; Neto et al., 2015; Susman et al., 2010),
one could predict that they would have the same effect on the
auto-inhibitory conformation of dynamin.
The most common dynamin 2 mutation R456W that causes
CNM (Böhm et al., 2012) is also positioned in the stalk domain,
but targets another intermolecular interface of the protein. It loca-
lises to the outer monomer, where it interfaces the BSE of the inner
monomer facing an asparagine and a lysine residue (Reubold et al.,
2015) (Fig. 3). The mutation of a polar and positively charged resi-
due (arginine) to a hydrophobic residue (tryptophan) could cause a
disruption of this interface, causing the same release of the auto-
inhibitory conformation than for mutations in the PH-stalk inter-
face. Consistently, the R456W mutation shares many aspects of
the phenotype of the stalk-PH mutations, being hyperactive and
Fig. 3. Dynamin tetramer structure. Structure of the dynamin tetramer (Reubold et al., 2015) with represented dynamin 2 CNM-related mutations. The inlets show the
interface between the stalk and the PH domain (right panel) and mutation R465W (left panel).
Table 2
CNM mutations in Dynamin 2.
Mutation Exon Domain Dominance Severity Disease onset Hyperactivitya of dynamin Reference of discovery
E368 K 8 Stalk (middle) Dominant Severe Neonatal or childhood Yes Bitoun et al. (2005)
E368Q 8 Stalk (middle) Dominant Variable Variable [Not tested] Echaniz-Laguna et al. (2007)
R369W 8 Stalk (middle) Dominant Mild Adolescence or adulthood Yes Bitoun et al. (2005)
R369Q 8 Stalk (middle) Dominant Mild Variable [Not tested] Bitoun et al. (2005)
F372C 8 Stalk (middle) Dominant Severe Childhood [Not tested] Neto et al. (2015)
V375G 8 Stalk (middle) Dominant Severe Neonatal [Not tested] Catteruccia et al. (2013)
R465W 11 Stalk (middle) Dominant Mild Variable Yes Bitoun et al. (2005)
R522C 15 PH Dominant Mild Variable [Not tested] Böhm et al. (2012)
R522H 15 PH Dominant Mild Variable [Not tested] Susman et al. (2010)
R523G 15 PH Dominant Mild Adulthood [Not tested] Böhm et al. (2012)
E540K 15 PH Dominant Severe Adulthood [Not tested] Catteruccia et al. (2013)
E560K 16 PH Dominant Severe Childhood Yes Bitoun et al. (2009a,b)
D614N 17 PH Dominant Mild Adulthood [Not tested] Kierdaszuk et al. (2013)
A618D 17 PH Dominant Mild Neonatal [Not tested] Melberg et al. (2010)
A618T 17 PH Dominant Severe Neonatal Yes Bitoun et al. (2007)
S619L 17 PH Dominant Severe Neonatal Yes Bitoun et al. (2007)
S619W 17 PH Dominant Severe Neonatal Yes Bitoun et al. (2007)
L621P 17 PH Dominant Severe Neonatal [Not tested] Bitoun et al. (2007)
DV625 17 PH Dominant Severe Neonatal Yes Bitoun et al. (2007)
P627R 17 PH Dominant Intermediate Neonatal or childhood [Not tested] Böhm et al. (2012)
P627H 17 PH Dominant Severe Childhood [Not tested] Susman et al. (2010)
E650K 18 Stalk (GED) Dominant Mild Childhood Yes Bitoun et al. (2009a,b)
Splice site mut. 17-18 PH-stalk (GED) Dominant Mild Variable [Not tested] Böhm et al. (2012)
a Basal activity and/or lipid-coupled activity.
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auto-inhibitory regulation.
The remaining known CNM-related dynamin 2 mutations
(R522C, R522H, R523G, E540K, E560K, E650K and donor splice site
deletion between exon 17 and 18; Bitoun et al., 2009a,b; Böhm
et al., 2012; Catteruccia et al., 2013; Jeub et al., 2008; Susman
et al., 2010) have not yet been biochemically or biologically char-
acterized and they all reside in the PH domain (except E650K,
located in the stalk domain) in regions probably necessary for
the interactions with lipids or the regulation of self-assembly upon
lipid interaction.But what could be the consequence of this gain of function onto
T-tubule biogenesis, and why would it be muscle-specific, since
these mutations appear on the ubiquitous form of dynamin 2?
Important clues came out from the in vivo analysis of these
mutants, both in endocytic and T-tubule biogenesis function of
dynamin 2: while overexpression of these mutations dramatically
impairs endocytosis in cultured cells, heterozygous patients’ cells
express the mutant and the wild-type at similar levels, and show
no defect in CME (Bitoun et al., 2009b; Koutsopoulos et al., 2011;
Sidiropoulos et al., 2012). Furthermore, in Mouse Embryonic
Fibroblasts (MEFs) from mice bearing the heterozygous R465W
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MEFs homozygous for these mutations (homozygous mice die after
birth) (Durieux et al., 2010). These findings show that the disease is
probably not related to the function of dynamin in CME, whose
alteration causes embryonic lethality, and that these mutations
seem to have very little effect on CME. Moreover, a gain of function
of dynamin 2 in CME is likely to have no physiological impact, as
CME would just go faster. However, a recent study has shown a
slight impairment in clathrin-independent EGF, cholera toxin
uptake and EGFR downregulation as well as a defect in trafficking
of p75 receptor from the Golgi to the plasma membrane in stable
cell lines expressing physiological levels of the hyperactive dyna-
min 2 mutations R465W and E368K (Liu et al., 2011). This may
cause signalling deregulation in these patients, which may account
for the severity of some forms.
As a conclusion, the biochemical, biological and clinical analysis
of CNM-related dynamin 2 mutations has shown that they have a
global gain of function with no dramatic impact on the ubiquitous
functions of dynamin 2 in CME. The pathology must therefore arise
from the alteration of another function of dynamin 2 delimited to a
muscle-specific role.
3.2. Gain of function dynamin 2 mutations alter a tissue-specific
balance
The fact that none of the ubiquitous functions of dynamin 2 are
defective in a heterozygous background of CNM-related dynamin 2
mutations leads to consider tissue-specific functions of dynamin 2
in the muscle. In muscle fibres, dynamin 2 has been found along
the Z-line, co-localizing with a-actinin and desmin. Dynamin 2 is
located in close proximity to dihydropyridine receptor (DHPR), a
marker of T-tubules (Cowling et al., 2011; Durieux et al., 2010),
which suggests that dynamin 2, like BIN1, could be implicated in
T-tubule biogenesis. The presence of dynamin 2 on T-tubules still
has to be shown. The analysis of CNM-related dynamin 2 muta-
tions in animal models and in cells strongly implicates that the
hyperactivation of dynamin 2 is deleterious to the maintenance
and stabilization of T-tubules and triads, suggesting a tissue-
specific role of dynamin in muscles related to T-tubule and triad
shaping. The expression of human dynamin 2 carrying the muta-
tion R465W in adult mice results in a decrease in muscle mass
due to the appearance of atrophic fibres. Histological analysis
showed misalignment of Z-lines and triad defects such as abnor-
mally shaped T-tubules and a swollen sarcoplasmic reticulum
(Cowling et al., 2011). In heterozygous mice for the same mutation,
a slight disorganization of T-tubules, sarcoplasmic reticulum and
an increase in cytosolic Ca2+ are also observed, although defects
in the triad structure are milder (Durieux et al., 2010).
Similar results have been obtained in non-mammalian organ-
isms, supporting a conserved role of dynamin 2 in T-tubule devel-
opment through evolution. In larvae of transgenic Drosophila
ectopically expressing one of the human dynamin 2 mutations
R465W, A618T or S619L in the muscle displayed fragmented
T-tubules even when expressed later in development when
T-tubules are already formed (Chin et al., 2015). In zebrafish,
where extensive disorganization of triad structures and T-tubule
fragmentation can be observed when the human dynamin 2
S619L mutant is expressed during development, these defects led
to impaired excitation-contraction coupling (Gibbs et al., 2014).
Altogether, these results suggest a tissue-specific function of
dynamin 2 in the establishment of the T-tubule structures in mus-
cle fibres. T-tubules are a result of plasma membrane tubulation
carried out most probably by caveolin-3 and BIN1. Dynamin 2
could either serve as a scaffolding protein as it is able to form a
more rigid scaffold then N-BAR proteins (Frost et al., 2008), which
could help the maintenance and the resistance of the T-tubulesystem needed for muscle contraction. An alternative hypothesis
is that dynamin 2 could be involved in T-tubule length regulation
through membrane fission. Another hint of a possible function of
dynamin in T-tubule shaping comes from the BIN1 mutant
K575X: its impairment of the SH3 domain, thus loss of interaction
with dynamin 2, could account for its pathological outcome in
patients (Nicot et al., 2007).
However, the fission activity of dynamin 2 must be blocked or
tightly regulated to play this role, otherwise dynamin would exces-
sively cut these T-tubules, leading to a fragmented T-tubule sys-
tem. In a wild type background, dynamin 2 fission activity
should be somehow inhibited or regulated at the T-tubule. This
also explains why gain-of function mutations would have a dra-
matic effect specifically at the T-tubule, as enhancing the fission
activity of dynamin 2 would cause disruption of the T-tubule sys-
tem. But how dynamin 2 fission activity would be specifically
inhibited at the T-tubule? As described in the following, this may
arise from its specific interaction with BIN1.
3.3. Interplay between dynamin, BIN1 and MTM1 functions in T-tubule
biogenesis
BIN1 may specifically recruit dynamin 2 to the T-tubule system
(Lee et al., 2002) and inhibit its fission activity. Supporting this
assertion, other N-BAR proteins such as endophilin and amphiphy-
sin regulate dynamin’s fission activity, but the nature of the regu-
lation (activation versus inhibition) seemed to vary for different N-
BAR proteins and in different conditions (Farsad et al., 2001;
Meinecke et al., 2013; Neumann and Schmid, 2013; Takei et al.,
1999). In some experiments (Boucrot et al., 2012; Farsad et al.,
2001), N-BAR proteins associated with dynamin have displayed
an inhibitory action on dynamin fission activity. Thus, one could
postulate that BIN1 and dynamin 2 form a heteropolymer that
would block dynamin 2’s ability to sever the membrane. However,
this effect has not been reproducibly established, and contradic-
tory results have been obtained (Meinecke et al., 2013; Neumann
and Schmid, 2013; Takei et al., 1999; Yoshida et al., 2004).
In muscle fibres expressing CNM-related dynamin 2 mutations,
the abnormal hyperactivity of these mutants could overcome the
inhibition of dynamin-fission activity, shifting the equilibrium
between dynamin 2 scaffolding with a controlled membrane fis-
sion function towards unregulated membrane fission. This would
result in the fragmented and abnormally shaped T-tubules, as
observed in the animal models expressing hyperactive dynamin
2 mutations (Chin et al., 2015; Gibbs et al., 2014).
Evidences supporting this model come from experiments in
cells. Upon overexpression of BIN1 (or other N-BAR proteins) in
cultured cells, an extensive membrane tubulation is observed. This
effect can be counteracted by overexpressing dynamin (Itoh et al.,
2005) or by expressing a CNM-related hyperactive mutation (Chin
et al., 2015; Gibbs et al., 2014). In these examples, the plasma
membrane tubulation is the result of an imbalance between the
tubulation activity of BIN1 (higher) and the fission activity of dyna-
min (lower): the balance can be restored by either increasing the
amount of dynamin, or by expressing a dynamin mutant with
increased activity.
Also, as described above, mutations in the SH3 domain of BIN1
could impair its interaction with dynamin 2, releasing dynamin’s
inhibition. In these mutants, dynamin 2 would not be inhibited
enough to allow for proper T-tubule maintenance. However, as
BIN1 also participates in the recruitment of dynamin 2 to the T-
tubule system, together with phosphoinositides, one may question
if the reduced recruitment of dynamin 2 in the SH3 BIN1 mutants
may counteract the reduced inhibition of dynamin fission activity.
In this context, the role of the phosphoinositides may be essential
to understand the mechanism of the disease. Myotubularin, the
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3-phosphatase that can interact with BIN1. In Royer et al. (2013),
the authors found that myotubularin (MTM1) binds BIN1 in vitro
and in skeletal muscle. Similar to the effect of binding of dynamin’s
PRD domain to BIN1, the authors propose that MTM1 may help
dynamin and BIN1 tubulating activity. It would also require
MTM1’s phosphatase activity. MTM1 is a 3-phosphatase and its
substrates are PI(3)P and PI(3,5)P2. As BIN1 was shown to bind to
PI(5)P as well as PI(4,5)P2 in contrast to PI(3,5)P2 (Fugier et al.,
2011; Lee et al., 2002; Picas et al., 2014), one can hypothesize that
MTM1might promote the formation of 5-phosphate phosphoinosi-
tides, such as PI(5)P and PI(4,5)P2, by increasing the level of their
precursors (PI and PI(5)P). These 5-phosphate phosphoinositides
will then recruit BIN1 and dynamin to the plasma or T-tubule
membrane.
Furthermore, Royer et al. (2013) observed that both Q573X and
K575X BIN1 mutants have an increased interaction with MTM1
in vitro. A plausible mechanism would thus be that the same
SH3 mutants of BIN1 have a decreased interaction with dynamin
and an increased interaction with MTM1. The defective recruit-
ment of dynamin by the BIN1 SH3 mutant could thus be compen-
sated by the increase of 5-phosphate phosphoinositides resulting
from a higher recruitment of MTM1 to BIN1 structures. However
in this case, dynamin’s fission activity would not be inhibited, since
the interaction with BIN1 is lost, and would thus lead to a dis-
rupted T-tubule system.
The BIN1-MTM1 interaction is also interesting when compared
with other N-BAR/phosphatase pairs: for example, endophilin
physically interacts with and recruits the lipid phosphatase synap-
tojanin to the membrane of clathrin-coated pits (Perera et al.,
2006). In the synaptojanin-endophilin case, the synaptojanin
recruitment is proposed to result in a decrease of the PI(4,5)P2 con-
centration and to allow for fission and uncoating of clathrin-coated
pits (Perera et al., 2006). The striking difference to the
synaptojanin-endophilin pair is that MTM1 recruitment by BIN1
should, via increasing the concentration of the PI(4,5)P2 precursor,
lead to an increase of PI(4,5)P2, which in turn would recruit more
BIN1 and dynamin. This opposite effect correlates nicely with the
idea that the scaffold which stabilises T-tubules would have a pos-
itive feedback loop where the scaffold proteins increase their
respective recruitment, whereas the scaffold and coat implicated
in the formation of a clathrin-coated vesicle is temporary.4. General conclusions
We have reviewed in this article how different groups of muta-
tions disturb the structure and function of BIN1, leading to CNM.
BIN1 mutations in the amphipathic helix could decrease BIN1’s
scaffolding properties on membrane tubes. Mutations in the tip
region of the BAR domain dimer may decrease BIN1’s tubulation
properties. Also in the case of splice-site mutations resulting in a
loss of the PI motif, BIN1 tubulates less and the T-tubule formation
and/or maintenance is impaired. In contrast, mutations in the SH3
domain do not impair BIN1’s curvature inducing features but
might affect both dynamin and MTM1 levels at the T-tubules.
CNM-related mutations in dynamin 2 are hyperactive and thus
correspond to a gain of function. As long as they are heterozygous,
they cannot impair clathrin-mediated endocytosis because they
maintain the ability to mediate membrane fission and their action
is regulated by redundant factors and regulators. In T-tubule bio-
genesis and maintenance, it is primarily the membrane scaffolding
and tubulation activities or a moderate fission activity of dynamin
that are at work. T-tubule biogenesis thus requires a down regula-
tion of dynamin 2’s intrinsic fission activity. Thus, dynamin 2
mutations that have increased fission activity which are notharmful for CME, probably cause massive problems in the T-
tubule system because of their inability to be down regulated.
Thus, the balance between membrane tubulating and fission activ-
ities of dynamin is crucial for the T-tubule biogenesis.
Given that CNM-associated dynamin mutants are hyperactive
and BIN1 mutants have a decrease-of-function, CNMs are one
example where an N-BAR protein seems to negatively regulate
dynamin’s fission activity. To test this hypothesis, one could over-
express dynamin 2 GTPase defective mutants in cells with CNM-
associated BIN1 mutations. If this rescues the low-function BIN1
phenotype (fragmented T-tubules), this would clearly speak for a
role of BIN1 in preventing dynamin from cutting T-tubules. Fitting
with this theory, a patent has been published for the idea to treat
CNM patients with dynamin inhibitors (Laporte and Cowling,
European Patent EP2862928A1).
Another interesting matter of the CNMs is its tissue-specificity
to muscles, while other cellular functions seemed unaffected by
the CNM mutations, even though most of the mutations affect
ubiquitously expressed exons of BIN1 and dynamin 2. We hypoth-
esize that the tissue-specificity of the pathology is due to the fact
that T-tubules are one of few cases where membrane tubules are
formed in cells and are required to be incredibly stable over time,
while they represent ideal targets for dynamin’s fission activity.
Thus a tight regulation of the levels of BIN1 and dynamin, as well
as of the balance between their specific activities is required in the
T-tubule system, with very little redundancy as compared to the
CME system. Most probably, the triple complex between dynamin
2, BIN1 and MTM1 is at the heart of this balance between mem-
brane tubulation and fission activity, as many of the mutations
found in these three proteins affect the protein-protein interaction
domains. Overall, if membrane deformation properties are too low,
the T-tubule formation is impaired. If fission activity is too high, T-
tubule are snapped too early after formation.
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